Motivyst

Uses
Motivyst (Canagliflozin) - 300mg (10 Tablets) is used to treat type 2 diabetes in adults. The therapy has to be combined with strict diet and regular physical exercise. The glycemia will be significantly improved as a result of monotherapy, as well as combination therapy with other other hypoglycemic medications.

Dosage and Administration
It is recommended to take Motivyst (Canagliflozin) by mouth once a day before breakfast. The recommended dose for adult type 2 diabetes patients will be 100 or 300 mg taken once a day. If Motivyst (Canagliflozin) is used as an addition to other medications (such as insulin or insuling-increasing medications), to reduce the risks of hypoglycemia the dose can be reduced.

Side effects
There has been special medical research to collect data on side effects of the medication. The received information was systematized based on every organ system and incidence rate.

The most common adverse effects caused by Motivyst (Canagliflozin) include the following:

• Digestive system (constipation, thirst, dry mouth);
• Kidneys and urinary system (urosepsis, urinary infections, polyuria, pollakiuria, urinary urgency);
• Mammary glands and reproductive system (balanitis, balanoposthitis, vaginal infections, vulvovaginal candidiasis).

The listed side effects can be induced by Motivyst (Canagliflozin) as a monotherapy medication and as part of the combination therapy along with pioglitazone and sulphonylurea.

Furthermore, other side effects may occur in patients suffering from type 2 diabetes, such as intravascular volume reduction, skin rash, and hives - these developed in placebo-controlled experiments with the incidence rate of less than 2%.

Precautions
Motivyst (Canagliflozin) is contraindicated to patients with the following conditions:

• Hypersensitivity to Canagliflozin or any other component of the medication;
• Type 1 diabetes;
• Diabetic ketoacidosis;
• Severe kidney failure;
• Severe liver failure;
• Pregnancy and breastfeeding;
• Age under 18 years.

The effects of the medication during pregnancy and breastfeeding have not been studied. In the experiments on animals, it has not been proved that Motivyst (Canagliflozin) has any direct or indirect toxic effect on the reproductive system. However, the use of the medication in female patients during pregnancy and breastfeeding is highly not recommended, because the active ingredient may be excreted into the breast milk, and the risks of this treatment may be not justified.